Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
European Society for Medical Oncology to hold a virtual meeting » 04:55
09/18/21
09/18
04:55
09/18/21
04:55
ABBV

AbbVie

$107.75 /

-0.33 (-0.31%)

, AYLA

Ayala Pharmaceuticals

$12.25 /

-0.01 (-0.08%)

, DCPH

Deciphera

$33.08 /

+1.45 (+4.58%)

, GMAB

Genmab

$43.10 /

+0.845 (+2.00%)

, LPTX

Leap Therapeutics

$2.65 /

+0.13 (+5.16%)

, ORIC

Oric Pharmaceuticals

$25.20 /

+0.99 (+4.09%)

, SYNH

Syneos Health

$94.34 /

+0.55 (+0.59%)

, BGNE

BeiGene

$403.60 /

+18.32 (+4.75%)

, BMY

Bristol-Myers

$61.32 /

+0.1 (+0.16%)

, BYSI

BeyondSpring

$23.00 /

+0.47 (+2.09%)

, CALA

Calithera Biosciences

$2.25 /

+0.2 (+9.76%)

, GILD

Gilead

$71.61 /

+0.34 (+0.48%)

, GH

Guardant Health

$132.01 /

+5.01 (+3.94%)

, LLY

Eli Lilly

$230.17 /

-0.78 (-0.34%)

, IPSEY

Ipsen

$23.92 /

-0.395 (-1.62%)

, EXAS

Exact Sciences

$108.29 /

+5.47 (+5.32%)

, IDYA

Ideaya Biosciences

$26.90 /

+0.9 (+3.46%)

, GSK

GlaxoSmithKline

$38.94 /

-0.16 (-0.41%)

, RHHBY

Roche

$46.07 /

-0.75 (-1.60%)

, REGN

Regeneron

$651.38 /

-2.3 (-0.35%)

, PFE

Pfizer

$43.89 /

-0.57 (-1.28%)

, TAK

Takeda Pharmaceutical

$17.16 /

-0.045 (-0.26%)

, TMO

Thermo Fisher

$596.98 /

+36.11 (+6.44%)

, TCRR

TCR2 Therapeutics

$10.00 /

-5.715 (-36.38%)

, VERU

Veru

$8.94 /

+0.17 (+1.94%)

, VBLT

VBL Therapeutics

$2.32 /

-0.035 (-1.49%)

, VTRS

Viatris

$13.57 /

-0.13 (-0.95%)

, NVS

Novartis

$83.49 /

-0.88 (-1.04%)

ESMO 2021 Virtual…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

GMAB Genmab
$43.10 /

+0.845 (+2.00%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

IPSEY Ipsen
$23.92 /

-0.395 (-1.62%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

VTRS Viatris
$13.57 /

-0.13 (-0.95%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
09/08/21 JPMorgan
AbbVie offers 'best risk/reward story in the group,' says JPMorgan
09/07/21 Morgan Stanley
Morgan Stanley cuts Vertex Pharmaceuticals to Underweight amid AbbVie overhang
AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with Buy, $29 target at Ladenburg
07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with a Buy at Ladenburg
12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

08/04/21 H.C. Wainwright
Deciphera price target lowered to $70 from $75 at H.C. Wainwright
05/05/21 Barclays
Deciphera price target lowered to $65 from $70 at Barclays
05/05/21 H.C. Wainwright
Deciphera price target lowered to $75 from $80 at H.C. Wainwright
05/05/21 Piper Sandler
Deciphera price target lowered to $60 from $75 at Piper Sandler
GMAB Genmab
$43.10 /

+0.845 (+2.00%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

09/16/21 Piper Sandler
Leap data show 'very favorable early signal,' says Piper Sandler
09/13/21 Raymond James
Leap Therapeutics price target raised to $4 from $3 at Raymond James
09/13/21 Piper Sandler
Leap combo sees 'strong' early response rate, says Piper Sandler
06/03/21 Baird
Leap Therapeutics transferred with Outperform at Baird
ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy after tumor data at Citi
07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
07/13/21 Barclays
Syneos Health price target raised to $102 from $90 at Barclays
06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

09/08/21 Baird
BeyondSpring initiated with an Outperform at Baird
08/04/21 Evercore ISI
BeyondSpring price target raised to $95 from $30 at Evercore ISI
08/04/21 William Blair
BeyondSpring may have new standard of care in lung cancer, says William Blair
08/04/21 H.C. Wainwright
Wainwright upgrades BeyondSpring with $100 target on lung cancer data
CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
GILD Gilead
$71.61 /

+0.34 (+0.48%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
GH Guardant Health
$132.01 /

+5.01 (+3.94%)

08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
IPSEY Ipsen
$23.92 /

-0.395 (-1.62%)

08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
08/02/21 Societe Generale
Ipsen price target raised to EUR 101 from EUR 90 at Societe Generale
07/30/21 Credit Suisse
Ipsen price target raised to EUR 90 from EUR 75 at Credit Suisse
EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/15/21 Canaccord
Exact Sciences progress in MRD space a positive, says Canaccord
09/01/21 Baird
UnitedHealth update to CRC screening coverage not a surprise, says Baird
IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

06/03/21 Baird
Ideaya Biosciences assumed with an Outperform at Baird
04/22/21 Roth Capital
Ideaya Biosciences price target raised to $38 from $31 at Roth Capital
04/19/21 H.C. Wainwright
Ideaya Biosciences price target raised to $35 from $29 at H.C. Wainwright
04/16/21 Roth Capital
Ideaya Biosciences price target raised to $31 from $23 at Roth Capital
GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
RHHBY Roche
$46.07 /

-0.75 (-1.60%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
REGN Regeneron
$651.38 /

-2.3 (-0.35%)

09/15/21 Cantor Fitzgerald
Regeneron price target raised to $700 from $670 at Cantor Fitzgerald
09/15/21 H.C. Wainwright
Regeneron price target raised to $831 from $787 at H.C. Wainwright
09/15/21 Piper Sandler
Regeneron price target raised to $690 from $675 at Piper Sandler
09/09/21
Fly Intel: Top five analyst initiations
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

08/03/21 Piper Sandler
Arcturus strength attributable to large pharma's interest in mRNA, says Piper
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

08/04/21 Credit Suisse
Thermo Fisher assumed with an Outperform at Credit Suisse
08/04/21 Argus
Thermo Fisher price target raised to $600 from $530 at Argus
07/29/21 Cowen
Thermo Fisher price target raised to $560 from $525 at Cowen
07/29/21 BTIG
Thermo Fisher price target raised to $610 from $590 at BTIG
TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

09/17/21 Wedbush
TCR2 Therapeutics downgraded to Neutral from Outperform at Wedbush
08/06/21 BMO Capital
TCR2 Therapeutics price target lowered to $44 from $53 at BMO Capital
06/24/21 Goldman Sachs
TCR2 Therapeutics initiated with a Buy at Goldman Sachs
06/11/21 BMO Capital
TCR2 Therapeutics coverage transferred at BMO Capital
VERU Veru
$8.94 /

+0.17 (+1.94%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
VTRS Viatris
$13.57 /

-0.13 (-0.95%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
NVS Novartis
$83.49 /

-0.88 (-1.04%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

VTRS Viatris
$13.57 /

-0.13 (-0.95%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

  • 08
    Jul
  • 03
    Jun
  • 04
    May
  • 09
    Apr
  • 01
    Mar
  • 18
    Feb
  • 20
    Jan
  • 02
    Dec
  • 02
    Dec
  • 19
    Nov
  • 13
    Nov
  • 07
    Oct
ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

GMAB Genmab
$43.10 /

+0.845 (+2.00%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

VTRS Viatris
$13.57 /

-0.13 (-0.95%)

Yesterday
Hot Stocks
Merck announces CHMP recommendation for approval of Keytruda » 07:17
09/17/21
09/17
07:17
09/17/21
07:17
MRK

Merck

$71.94 /

-0.87 (-1.19%)

Merck announced the…

Merck announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has recommended approval of Keytruda, Merck's anti-PD-1 therapy, in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer, or TNBC, in adults whose tumors express PD-L1 and who have not received prior chemotherapy for metastatic disease. The positive opinion is based on progression-free survival, or PFS, and overall survival, or OS, results from the Phase 3 KEYNOTE-355 trial, which showed that treatment with Keytruda in combination with chemotherapy as compared to chemotherapy alone, significantly improved PFS and OS in these patients. Overall survival data from KEYNOTE-355 will be presented at the European Society for Medical Oncology, or ESMO, Congress on September 19. The CHMP's recommendation will now be reviewed by the European Commission for marketing authorization in the European Union.

ShowHide Related Items >><<
MRK Merck
$71.94 /

-0.87 (-1.19%)

MRK Merck
$71.94 /

-0.87 (-1.19%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley downgrades Merck to Equal Weight, awaits strategic action
09/07/21 Morgan Stanley
Merck downgraded to Equal Weight from Overweight at Morgan Stanley
MRK Merck
$71.94 /

-0.87 (-1.19%)

MRK Merck
$71.94 /

-0.87 (-1.19%)

MRK Merck
$71.94 /

-0.87 (-1.19%)

MRK Merck
$71.94 /

-0.87 (-1.19%)

Hot Stocks
Roche announces positive CHMP opinion for Gavreto in NSCLC with RET fusions » 07:17
09/17/21
09/17
07:17
09/17/21
07:17
RHHBY

Roche

$46.82 /

-0.04 (-0.09%)

Roche announced that the…

Roche announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of Gavreto as a monotherapy for the treatment of adult patients with rearranged during transfection, or RET, fusion-positive advanced non-small cell lung cancer, or NSCLC, not previously treated with a RET inhibitor. "This positive CHMP opinion for Gavreto represents another important step towards our goal of providing effective therapeutics that target genomic drivers of disease for as many cancer patients as possible," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development.

ShowHide Related Items >><<
RHHBY Roche
$46.82 /

-0.04 (-0.09%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
RHHBY Roche
$46.82 /

-0.04 (-0.09%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

Conference/Events
BofA to hold a virtual conference » 04:55
09/17/21
09/17
04:55
09/17/21
04:55
RHHBY

Roche

$46.82 /

-0.04 (-0.09%)

, ALLO

Allogene Therapeutics

$24.53 /

-0.42 (-1.68%)

, ATR

AptarGroup

$122.29 /

-2.415 (-1.94%)

, FMS

Fresenius Medical

$35.31 /

-0.36 (-1.01%)

, SNY

Sanofi

$48.20 /

+0.185 (+0.39%)

, WAT

Waters

$399.60 /

-10.23 (-2.50%)

, ALNY

Alnylam

$190.23 /

+2.63 (+1.40%)

, BLUE

Bluebird Bio

$17.67 /

-0.12 (-0.67%)

, AZN

AstraZeneca

$56.60 /

+0.14 (+0.25%)

, EXEL

Exelixis

$20.53 /

+0.04 (+0.20%)

, FOLD

Amicus

$11.09 /

-0.06 (-0.54%)

, PFE

Pfizer

$44.46 /

-0.31 (-0.69%)

, PAHC

Phibro Animal Health

$21.32 /

-0.08 (-0.37%)

, QGEN

Qiagen

$54.15 /

+0.6601 (+1.23%)

, IONS

Ionis Pharmaceuticals

$36.45 /

-0.55 (-1.49%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference to be held on September 15-17.

ShowHide Related Items >><<
WAT Waters
$399.60 /

-10.23 (-2.50%)

SNY Sanofi
$48.20 /

+0.185 (+0.39%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

QGEN Qiagen
$54.15 /

+0.6601 (+1.23%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

FOLD Amicus
$11.09 /

-0.06 (-0.54%)

FMS Fresenius Medical
$35.31 /

-0.36 (-1.01%)

EXEL Exelixis
$20.53 /

+0.04 (+0.20%)

BLUE Bluebird Bio
$17.67 /

-0.12 (-0.67%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

ATR AptarGroup
$122.29 /

-2.415 (-1.94%)

ALNY Alnylam
$190.23 /

+2.63 (+1.40%)

ALLO Allogene Therapeutics
$24.53 /

-0.42 (-1.68%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
ALLO Allogene Therapeutics
$24.53 /

-0.42 (-1.68%)

08/06/21 B. Riley
Allogene Therapeutics price target lowered to $40 from $52 at B. Riley
08/05/21 Oppenheimer
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer
08/05/21 Oppenheimer
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer
06/21/21 Jefferies
Allogene Therapeutics assumed with a Buy at Jefferies
ATR AptarGroup
$122.29 /

-2.415 (-1.94%)

09/13/21 Baird
AptarGroup price target lowered to $135 from $150 at Baird
08/02/21 William Blair
William Blair downgrades AptarGroup after 'underwhelming quarter'
08/02/21 William Blair
AptarGroup downgraded to Market Perform from Outperform at William Blair
04/19/21 Deutsche Bank
AptarGroup price target raised to $162 from $152 at Deutsche Bank
FMS Fresenius Medical
$35.31 /

-0.36 (-1.01%)

09/10/21 Barclays
Fresenius Medical downgraded to Equal Weight from Overweight at Barclays
09/10/21 JPMorgan
Fresenius Medical downgraded to Underweight from Neutral at JPMorgan
08/11/21 JPMorgan
Fresenius Medical price target raised to EUR 61.30 from EUR 58.80 at JPMorgan
08/04/21 Societe Generale
Fresenius Medical price target raised to EUR 71 from EUR 64 at Societe Generale
SNY Sanofi
$48.20 /

+0.185 (+0.39%)

09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
WAT Waters
$399.60 /

-10.23 (-2.50%)

08/04/21 SVB Leerink
Waters price target raised to $385 from $370 at SVB Leerink
08/04/21 Baird
Waters price target raised to $360 from $297 at Baird
08/04/21 Citi
Waters price target raised to $400 from $315 at Citi
07/06/21 Evercore ISI
Evercore ISI upgrades Waters to Outperform on turnaround progress
ALNY Alnylam
$190.23 /

+2.63 (+1.40%)

08/27/21 BMO Capital
Alnylam price target raised to $196 from $174 at BMO Capital
08/04/21 Barclays
Alnylam price target raised to $216 from $196 at Barclays
08/04/21 Piper Sandler
Alnylam downgraded to Neutral from Overweight at Piper Sandler
06/30/21 Piper Sandler
Alnylam's zilebesiran has 'best in class' potential, says Piper Sandler
BLUE Bluebird Bio
$17.67 /

-0.12 (-0.67%)

08/10/21
Fly Intel: Top five analyst downgrades
08/10/21 BMO Capital
Bluebird Bio price target lowered to $21 from $29 at BMO Capital
08/10/21 Canaccord
Bluebird Bio downgraded to Hold from Buy at Canaccord
08/10/21 Mizuho
Bluebird Bio price target lowered to $29 from $70 at Mizuho
AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
08/11/21 Goldman Sachs
FibroGen price target lowered to $16 from $22 at Goldman Sachs
08/09/21 Morgan Stanley
AstraZeneca resumed with an Overweight at Morgan Stanley
EXEL Exelixis
$20.53 /

+0.04 (+0.20%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
FOLD Amicus
$11.09 /

-0.06 (-0.54%)

07/19/21 BTIG
Amicus assumed with a Buy at BTIG
07/09/21 Chardan
Amicus coverage transferred at Chardan
07/01/21 Berenberg
Amicus assumed with a Hold at Berenberg
05/27/21 Needham
Amicus initiated with a Hold at Needham
PFE Pfizer
$44.46 /

-0.31 (-0.69%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/13/21 JPMorgan
Pfizer price target raised to $42 from $40 at JPMorgan
PAHC Phibro Animal Health
$21.32 /

-0.08 (-0.37%)

08/04/21 Credit Suisse
Phibro Animal Health assumed with a Neutral at Credit Suisse
07/07/21
Fly Intel: Top five analyst downgrades
07/07/21 Barclays
Phibro Animal Health downgraded to Underweight from Equal Weight at Barclays
QGEN Qiagen
$54.15 /

+0.6601 (+1.23%)

07/14/21 Citi
Qiagen price target lowered to $58 from $65 at Citi
07/14/21 Kepler Cheuvreux
Qiagen downgraded to Hold from Buy at Kepler Cheuvreux
06/11/21 Berenberg
Qiagen price target lowered to EUR 54 from EUR 56 at Berenberg
06/03/21 Goldman Sachs
Qiagen initiated with a Neutral at Goldman Sachs
IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

07/15/21 Canaccord
Bicycle Therapeutics price target raised to $40 from $36 at Canaccord
07/14/21 Benchmark
Bicycle deal 'makes little sense' for Ionis, says Benchmark
07/13/21 William Blair
Bicycle collaboration a positive for Ionis, says William Blair
07/13/21 Piper Sandler
Bicycle Therapeutics price target raised to $46 from $39 at Piper Sandler
WAT Waters
$399.60 /

-10.23 (-2.50%)

SNY Sanofi
$48.20 /

+0.185 (+0.39%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

QGEN Qiagen
$54.15 /

+0.6601 (+1.23%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

PAHC Phibro Animal Health
$21.32 /

-0.08 (-0.37%)

IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

FOLD Amicus
$11.09 /

-0.06 (-0.54%)

EXEL Exelixis
$20.53 /

+0.04 (+0.20%)

BLUE Bluebird Bio
$17.67 /

-0.12 (-0.67%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

ATR AptarGroup
$122.29 /

-2.415 (-1.94%)

ALNY Alnylam
$190.23 /

+2.63 (+1.40%)

ALLO Allogene Therapeutics
$24.53 /

-0.42 (-1.68%)

SNY Sanofi
$48.20 /

+0.185 (+0.39%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

SNY Sanofi
$48.20 /

+0.185 (+0.39%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

QGEN Qiagen
$54.15 /

+0.6601 (+1.23%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

FOLD Amicus
$11.09 /

-0.06 (-0.54%)

FMS Fresenius Medical
$35.31 /

-0.36 (-1.01%)

EXEL Exelixis
$20.53 /

+0.04 (+0.20%)

BLUE Bluebird Bio
$17.67 /

-0.12 (-0.67%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

ALNY Alnylam
$190.23 /

+2.63 (+1.40%)

ALLO Allogene Therapeutics
$24.53 /

-0.42 (-1.68%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

Conference/Events
European Society for Medical Oncology to hold a virtual meeting » 04:55
09/17/21
09/17
04:55
09/17/21
04:55
ABBV

AbbVie

$108.08 /

+0.29 (+0.27%)

, AYLA

Ayala Pharmaceuticals

$12.26 /

-1.76 (-12.55%)

, DCPH

Deciphera

$31.77 /

+0.72 (+2.32%)

, GMAB

Genmab

$42.26 /

-0.575 (-1.34%)

, LPTX

Leap Therapeutics

$2.52 /

+0.57 (+29.23%)

, ORIC

Oric Pharmaceuticals

$24.49 /

-0.31 (-1.25%)

, SYNH

Syneos Health

$93.78 /

+0.07 (+0.07%)

, BGNE

BeiGene

$385.26 /

+10.94 (+2.92%)

, BMY

Bristol-Myers

$61.22 /

-0.78 (-1.26%)

, BYSI

BeyondSpring

$22.50 /

-0.48 (-2.09%)

, CALA

Calithera Biosciences

$2.05 /

-0.04 (-1.91%)

, GILD

Gilead

$71.32 /

-0.45 (-0.63%)

, GH

Guardant Health

$127.00 /

-0.01 (-0.01%)

, LLY

Eli Lilly

$230.95 /

-2.72 (-1.16%)

, IPSEY

Ipsen

$24.32 /

+0.23 (+0.95%)

, EXAS

Exact Sciences

$102.81 /

-1.83 (-1.75%)

, IDYA

Ideaya Biosciences

$25.90 /

-0.1 (-0.38%)

, GSK

GlaxoSmithKline

$39.10 /

-0.11 (-0.28%)

, RHHBY

Roche

$46.82 /

-0.04 (-0.09%)

, REGN

Regeneron

$652.73 /

+2.13 (+0.33%)

, PFE

Pfizer

$44.46 /

-0.31 (-0.69%)

, TAK

Takeda Pharmaceutical

$17.21 /

+0.205 (+1.21%)

, TMO

Thermo Fisher

$560.75 /

-2.085 (-0.37%)

, TCRR

TCR2 Therapeutics

$15.71 /

-0.51 (-3.14%)

, VERU

Veru

$8.76 /

-0.04 (-0.45%)

, VBLT

VBL Therapeutics

$2.35 /

+0.055 (+2.40%)

, VTRS

Viatris

$13.70 /

-0.03 (-0.22%)

, NVS

Novartis

$84.37 /

-0.695 (-0.82%)

ESMO 2021 Virtual…

ESMO 2021 Virtual Congress will be held on September 16-21. Webcast Link

ShowHide Related Items >><<
VTRS Viatris
$13.70 /

-0.03 (-0.22%)

VERU Veru
$8.76 /

-0.04 (-0.45%)

VBLT VBL Therapeutics
$2.35 /

+0.055 (+2.40%)

TMO Thermo Fisher
$560.75 /

-2.085 (-0.37%)

TCRR TCR2 Therapeutics
$15.71 /

-0.51 (-3.14%)

TAK Takeda Pharmaceutical
$17.21 /

+0.205 (+1.21%)

SYNH Syneos Health
$93.78 /

+0.07 (+0.07%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

REGN Regeneron
$652.73 /

+2.13 (+0.33%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

ORIC Oric Pharmaceuticals
$24.49 /

-0.31 (-1.25%)

NVS Novartis
$84.37 /

-0.695 (-0.82%)

LPTX Leap Therapeutics
$2.52 /

+0.57 (+29.23%)

LLY Eli Lilly
$230.95 /

-2.72 (-1.16%)

IPSEY Ipsen
$24.32 /

+0.23 (+0.95%)

IDYA Ideaya Biosciences
$25.90 /

-0.1 (-0.38%)

GSK GlaxoSmithKline
$39.10 /

-0.11 (-0.28%)

GMAB Genmab
$42.26 /

-0.575 (-1.34%)

GILD Gilead
$71.32 /

-0.45 (-0.63%)

GH Guardant Health
$127.00 /

-0.01 (-0.01%)

EXAS Exact Sciences
$102.81 /

-1.83 (-1.75%)

DCPH Deciphera
$31.77 /

+0.72 (+2.32%)

CALA Calithera Biosciences
$2.05 /

-0.04 (-1.91%)

BYSI BeyondSpring
$22.50 /

-0.48 (-2.09%)

BMY Bristol-Myers
$61.22 /

-0.78 (-1.26%)

BGNE BeiGene
$385.26 /

+10.94 (+2.92%)

AYLA Ayala Pharmaceuticals
$12.26 /

-1.76 (-12.55%)

ABBV AbbVie
$108.08 /

+0.29 (+0.27%)

ABBV AbbVie
$108.08 /

+0.29 (+0.27%)

09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
09/08/21 JPMorgan
AbbVie offers 'best risk/reward story in the group,' says JPMorgan
09/07/21 Morgan Stanley
Morgan Stanley cuts Vertex Pharmaceuticals to Underweight amid AbbVie overhang
AYLA Ayala Pharmaceuticals
$12.26 /

-1.76 (-12.55%)

07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with Buy, $29 target at Ladenburg
07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with a Buy at Ladenburg
12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
DCPH Deciphera
$31.77 /

+0.72 (+2.32%)

08/04/21 H.C. Wainwright
Deciphera price target lowered to $70 from $75 at H.C. Wainwright
05/05/21 Barclays
Deciphera price target lowered to $65 from $70 at Barclays
05/05/21 H.C. Wainwright
Deciphera price target lowered to $75 from $80 at H.C. Wainwright
05/05/21 Piper Sandler
Deciphera price target lowered to $60 from $75 at Piper Sandler
GMAB Genmab
$42.26 /

-0.575 (-1.34%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
LPTX Leap Therapeutics
$2.52 /

+0.57 (+29.23%)

09/16/21 Piper Sandler
Leap data show 'very favorable early signal,' says Piper Sandler
09/13/21 Raymond James
Leap Therapeutics price target raised to $4 from $3 at Raymond James
09/13/21 Piper Sandler
Leap combo sees 'strong' early response rate, says Piper Sandler
06/03/21 Baird
Leap Therapeutics transferred with Outperform at Baird
ORIC Oric Pharmaceuticals
$24.49 /

-0.31 (-1.25%)

07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy after tumor data at Citi
07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
SYNH Syneos Health
$93.78 /

+0.07 (+0.07%)

08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
07/13/21 Barclays
Syneos Health price target raised to $102 from $90 at Barclays
06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
BGNE BeiGene
$385.26 /

+10.94 (+2.92%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
BMY Bristol-Myers
$61.22 /

-0.78 (-1.26%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
BYSI BeyondSpring
$22.50 /

-0.48 (-2.09%)

09/08/21 Baird
BeyondSpring initiated with an Outperform at Baird
08/04/21 Evercore ISI
BeyondSpring price target raised to $95 from $30 at Evercore ISI
08/04/21 William Blair
BeyondSpring may have new standard of care in lung cancer, says William Blair
08/04/21 H.C. Wainwright
Wainwright upgrades BeyondSpring with $100 target on lung cancer data
CALA Calithera Biosciences
$2.05 /

-0.04 (-1.91%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
GILD Gilead
$71.32 /

-0.45 (-0.63%)

07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
GH Guardant Health
$127.00 /

-0.01 (-0.01%)

08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
LLY Eli Lilly
$230.95 /

-2.72 (-1.16%)

09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
IPSEY Ipsen
$24.32 /

+0.23 (+0.95%)

08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
08/02/21 Societe Generale
Ipsen price target raised to EUR 101 from EUR 90 at Societe Generale
07/30/21 Credit Suisse
Ipsen price target raised to EUR 90 from EUR 75 at Credit Suisse
EXAS Exact Sciences
$102.81 /

-1.83 (-1.75%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/15/21 Canaccord
Exact Sciences progress in MRD space a positive, says Canaccord
09/01/21 Baird
UnitedHealth update to CRC screening coverage not a surprise, says Baird
IDYA Ideaya Biosciences
$25.90 /

-0.1 (-0.38%)

06/03/21 Baird
Ideaya Biosciences assumed with an Outperform at Baird
04/22/21 Roth Capital
Ideaya Biosciences price target raised to $38 from $31 at Roth Capital
04/19/21 H.C. Wainwright
Ideaya Biosciences price target raised to $35 from $29 at H.C. Wainwright
04/16/21 Roth Capital
Ideaya Biosciences price target raised to $31 from $23 at Roth Capital
GSK GlaxoSmithKline
$39.10 /

-0.11 (-0.28%)

08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
RHHBY Roche
$46.82 /

-0.04 (-0.09%)

09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
REGN Regeneron
$652.73 /

+2.13 (+0.33%)

09/15/21 Cantor Fitzgerald
Regeneron price target raised to $700 from $670 at Cantor Fitzgerald
09/15/21 H.C. Wainwright
Regeneron price target raised to $831 from $787 at H.C. Wainwright
09/15/21 Piper Sandler
Regeneron price target raised to $690 from $675 at Piper Sandler
09/09/21
Fly Intel: Top five analyst initiations
PFE Pfizer
$44.46 /

-0.31 (-0.69%)

09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/13/21 JPMorgan
Pfizer price target raised to $42 from $40 at JPMorgan
TAK Takeda Pharmaceutical
$17.21 /

+0.205 (+1.21%)

08/03/21 Piper Sandler
Arcturus strength attributable to large pharma's interest in mRNA, says Piper
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
TMO Thermo Fisher
$560.75 /

-2.085 (-0.37%)

08/04/21 Credit Suisse
Thermo Fisher assumed with an Outperform at Credit Suisse
08/04/21 Argus
Thermo Fisher price target raised to $600 from $530 at Argus
07/29/21 Cowen
Thermo Fisher price target raised to $560 from $525 at Cowen
07/29/21 BTIG
Thermo Fisher price target raised to $610 from $590 at BTIG
TCRR TCR2 Therapeutics
$15.71 /

-0.51 (-3.14%)

08/06/21 BMO Capital
TCR2 Therapeutics price target lowered to $44 from $53 at BMO Capital
06/24/21 Goldman Sachs
TCR2 Therapeutics initiated with a Buy at Goldman Sachs
06/11/21 BMO Capital
TCR2 Therapeutics coverage transferred at BMO Capital
05/14/21 Wedbush
TCR2 Therapeutics price target lowered to $45 from $57 at Wedbush
VERU Veru
$8.76 /

-0.04 (-0.45%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VBLT VBL Therapeutics
$2.35 /

+0.055 (+2.40%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
VTRS Viatris
$13.70 /

-0.03 (-0.22%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
NVS Novartis
$84.37 /

-0.695 (-0.82%)

09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
VTRS Viatris
$13.70 /

-0.03 (-0.22%)

VERU Veru
$8.76 /

-0.04 (-0.45%)

VBLT VBL Therapeutics
$2.35 /

+0.055 (+2.40%)

TMO Thermo Fisher
$560.75 /

-2.085 (-0.37%)

TCRR TCR2 Therapeutics
$15.71 /

-0.51 (-3.14%)

TAK Takeda Pharmaceutical
$17.21 /

+0.205 (+1.21%)

SYNH Syneos Health
$93.78 /

+0.07 (+0.07%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

REGN Regeneron
$652.73 /

+2.13 (+0.33%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

ORIC Oric Pharmaceuticals
$24.49 /

-0.31 (-1.25%)

NVS Novartis
$84.37 /

-0.695 (-0.82%)

LPTX Leap Therapeutics
$2.52 /

+0.57 (+29.23%)

LLY Eli Lilly
$230.95 /

-2.72 (-1.16%)

IDYA Ideaya Biosciences
$25.90 /

-0.1 (-0.38%)

GSK GlaxoSmithKline
$39.10 /

-0.11 (-0.28%)

GILD Gilead
$71.32 /

-0.45 (-0.63%)

GH Guardant Health
$127.00 /

-0.01 (-0.01%)

EXAS Exact Sciences
$102.81 /

-1.83 (-1.75%)

DCPH Deciphera
$31.77 /

+0.72 (+2.32%)

CALA Calithera Biosciences
$2.05 /

-0.04 (-1.91%)

BYSI BeyondSpring
$22.50 /

-0.48 (-2.09%)

BMY Bristol-Myers
$61.22 /

-0.78 (-1.26%)

BGNE BeiGene
$385.26 /

+10.94 (+2.92%)

AYLA Ayala Pharmaceuticals
$12.26 /

-1.76 (-12.55%)

ABBV AbbVie
$108.08 /

+0.29 (+0.27%)

  • 08
    Jul
  • 03
    Jun
  • 04
    May
  • 09
    Apr
  • 01
    Mar
  • 18
    Feb
  • 20
    Jan
  • 02
    Dec
  • 02
    Dec
  • 19
    Nov
  • 13
    Nov
  • 07
    Oct
TMO Thermo Fisher
$560.75 /

-2.085 (-0.37%)

TAK Takeda Pharmaceutical
$17.21 /

+0.205 (+1.21%)

SYNH Syneos Health
$93.78 /

+0.07 (+0.07%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

REGN Regeneron
$652.73 /

+2.13 (+0.33%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

NVS Novartis
$84.37 /

-0.695 (-0.82%)

LLY Eli Lilly
$230.95 /

-2.72 (-1.16%)

GSK GlaxoSmithKline
$39.10 /

-0.11 (-0.28%)

GILD Gilead
$71.32 /

-0.45 (-0.63%)

EXAS Exact Sciences
$102.81 /

-1.83 (-1.75%)

BMY Bristol-Myers
$61.22 /

-0.78 (-1.26%)

BGNE BeiGene
$385.26 /

+10.94 (+2.92%)

ABBV AbbVie
$108.08 /

+0.29 (+0.27%)

VERU Veru
$8.76 /

-0.04 (-0.45%)

TMO Thermo Fisher
$560.75 /

-2.085 (-0.37%)

TAK Takeda Pharmaceutical
$17.21 /

+0.205 (+1.21%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

REGN Regeneron
$652.73 /

+2.13 (+0.33%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

ORIC Oric Pharmaceuticals
$24.49 /

-0.31 (-1.25%)

NVS Novartis
$84.37 /

-0.695 (-0.82%)

LPTX Leap Therapeutics
$2.52 /

+0.57 (+29.23%)

LLY Eli Lilly
$230.95 /

-2.72 (-1.16%)

IDYA Ideaya Biosciences
$25.90 /

-0.1 (-0.38%)

GSK GlaxoSmithKline
$39.10 /

-0.11 (-0.28%)

GMAB Genmab
$42.26 /

-0.575 (-1.34%)

GILD Gilead
$71.32 /

-0.45 (-0.63%)

GH Guardant Health
$127.00 /

-0.01 (-0.01%)

EXAS Exact Sciences
$102.81 /

-1.83 (-1.75%)

BYSI BeyondSpring
$22.50 /

-0.48 (-2.09%)

BMY Bristol-Myers
$61.22 /

-0.78 (-1.26%)

ABBV AbbVie
$108.08 /

+0.29 (+0.27%)

VTRS Viatris
$13.70 /

-0.03 (-0.22%)

VERU Veru
$8.76 /

-0.04 (-0.45%)

TAK Takeda Pharmaceutical
$17.21 /

+0.205 (+1.21%)

REGN Regeneron
$652.73 /

+2.13 (+0.33%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

LLY Eli Lilly
$230.95 /

-2.72 (-1.16%)

GSK GlaxoSmithKline
$39.10 /

-0.11 (-0.28%)

GILD Gilead
$71.32 /

-0.45 (-0.63%)

BYSI BeyondSpring
$22.50 /

-0.48 (-2.09%)

BMY Bristol-Myers
$61.22 /

-0.78 (-1.26%)

ABBV AbbVie
$108.08 /

+0.29 (+0.27%)

Thursday
Conference/Events
BofA to hold a virtual conference » 10:13
09/16/21
09/16
10:13
09/16/21
10:13
RHHBY

Roche

$46.86 /

+0.11 (+0.24%)

, ALLO

Allogene Therapeutics

$24.58 /

-0.37 (-1.48%)

, ATR

AptarGroup

$123.60 /

-1.1 (-0.88%)

, FMS

Fresenius Medical

$35.25 /

-0.42 (-1.18%)

, SNY

Sanofi

$48.22 /

+0.21 (+0.44%)

, WAT

Waters

$407.50 /

-2.335 (-0.57%)

, ALNY

Alnylam

$188.20 /

+0.595 (+0.32%)

, BLUE

Bluebird Bio

$17.50 /

-0.29 (-1.63%)

, AZN

AstraZeneca

$56.25 /

-0.21 (-0.37%)

, EXEL

Exelixis

$20.31 /

-0.18 (-0.88%)

, FOLD

Amicus

$11.02 /

-0.13 (-1.17%)

, PFE

Pfizer

$44.71 /

-0.06 (-0.13%)

, PAHC

Phibro Animal Health

$21.37 /

-0.03 (-0.14%)

, QGEN

Qiagen

$53.51 /

+0.02 (+0.04%)

, IONS

Ionis Pharmaceuticals

$36.23 /

-0.77 (-2.08%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference to be held on September 15-17.

ShowHide Related Items >><<
WAT Waters
$407.50 /

-2.335 (-0.57%)

SNY Sanofi
$48.22 /

+0.21 (+0.44%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

QGEN Qiagen
$53.51 /

+0.02 (+0.04%)

PFE Pfizer
$44.71 /

-0.06 (-0.13%)

IONS Ionis Pharmaceuticals
$36.23 /

-0.77 (-2.08%)

FOLD Amicus
$11.02 /

-0.13 (-1.17%)

FMS Fresenius Medical
$35.25 /

-0.42 (-1.18%)

EXEL Exelixis
$20.31 /

-0.18 (-0.88%)

BLUE Bluebird Bio
$17.50 /

-0.29 (-1.63%)

AZN AstraZeneca
$56.25 /

-0.21 (-0.37%)

ATR AptarGroup
$123.60 /

-1.1 (-0.88%)

ALNY Alnylam
$188.20 /

+0.595 (+0.32%)

ALLO Allogene Therapeutics
$24.58 /

-0.37 (-1.48%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
ALLO Allogene Therapeutics
$24.58 /

-0.37 (-1.48%)

08/06/21 B. Riley
Allogene Therapeutics price target lowered to $40 from $52 at B. Riley
08/05/21 Oppenheimer
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer
08/05/21 Oppenheimer
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer
06/21/21 Jefferies
Allogene Therapeutics assumed with a Buy at Jefferies
ATR AptarGroup
$123.60 /

-1.1 (-0.88%)

09/13/21 Baird
AptarGroup price target lowered to $135 from $150 at Baird
08/02/21 William Blair
William Blair downgrades AptarGroup after 'underwhelming quarter'
08/02/21 William Blair
AptarGroup downgraded to Market Perform from Outperform at William Blair
04/19/21 Deutsche Bank
AptarGroup price target raised to $162 from $152 at Deutsche Bank
FMS Fresenius Medical
$35.25 /

-0.42 (-1.18%)

09/10/21 Barclays
Fresenius Medical downgraded to Equal Weight from Overweight at Barclays
09/10/21 JPMorgan
Fresenius Medical downgraded to Underweight from Neutral at JPMorgan
08/11/21 JPMorgan
Fresenius Medical price target raised to EUR 61.30 from EUR 58.80 at JPMorgan
08/04/21 Societe Generale
Fresenius Medical price target raised to EUR 71 from EUR 64 at Societe Generale
SNY Sanofi
$48.22 /

+0.21 (+0.44%)

09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
WAT Waters
$407.50 /

-2.335 (-0.57%)

08/04/21 SVB Leerink
Waters price target raised to $385 from $370 at SVB Leerink
08/04/21 Baird
Waters price target raised to $360 from $297 at Baird
08/04/21 Citi
Waters price target raised to $400 from $315 at Citi
07/06/21 Evercore ISI
Evercore ISI upgrades Waters to Outperform on turnaround progress
ALNY Alnylam
$188.20 /

+0.595 (+0.32%)

08/27/21 BMO Capital
Alnylam price target raised to $196 from $174 at BMO Capital
08/04/21 Barclays
Alnylam price target raised to $216 from $196 at Barclays
08/04/21 Piper Sandler
Alnylam downgraded to Neutral from Overweight at Piper Sandler
06/30/21 Piper Sandler
Alnylam's zilebesiran has 'best in class' potential, says Piper Sandler
BLUE Bluebird Bio
$17.50 /

-0.29 (-1.63%)

08/10/21
Fly Intel: Top five analyst downgrades
08/10/21 BMO Capital
Bluebird Bio price target lowered to $21 from $29 at BMO Capital
08/10/21 Canaccord
Bluebird Bio downgraded to Hold from Buy at Canaccord
08/10/21 Mizuho
Bluebird Bio price target lowered to $29 from $70 at Mizuho
AZN AstraZeneca
$56.25 /

-0.21 (-0.37%)

08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
08/11/21 Goldman Sachs
FibroGen price target lowered to $16 from $22 at Goldman Sachs
08/09/21 Morgan Stanley
AstraZeneca resumed with an Overweight at Morgan Stanley
EXEL Exelixis
$20.31 /

-0.18 (-0.88%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
FOLD Amicus
$11.02 /

-0.13 (-1.17%)

07/19/21 BTIG
Amicus assumed with a Buy at BTIG
07/09/21 Chardan
Amicus coverage transferred at Chardan
07/01/21 Berenberg
Amicus assumed with a Hold at Berenberg
05/27/21 Needham
Amicus initiated with a Hold at Needham
PFE Pfizer
$44.71 /

-0.06 (-0.13%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/13/21 JPMorgan
Pfizer price target raised to $42 from $40 at JPMorgan
PAHC Phibro Animal Health
$21.37 /

-0.03 (-0.14%)

08/04/21 Credit Suisse
Phibro Animal Health assumed with a Neutral at Credit Suisse
07/07/21
Fly Intel: Top five analyst downgrades
07/07/21 Barclays
Phibro Animal Health downgraded to Underweight from Equal Weight at Barclays
QGEN Qiagen
$53.51 /

+0.02 (+0.04%)

07/14/21 Citi
Qiagen price target lowered to $58 from $65 at Citi
07/14/21 Kepler Cheuvreux
Qiagen downgraded to Hold from Buy at Kepler Cheuvreux
06/11/21 Berenberg
Qiagen price target lowered to EUR 54 from EUR 56 at Berenberg
06/03/21 Goldman Sachs
Qiagen initiated with a Neutral at Goldman Sachs
IONS Ionis Pharmaceuticals
$36.23 /

-0.77 (-2.08%)

07/15/21 Canaccord
Bicycle Therapeutics price target raised to $40 from $36 at Canaccord
07/14/21 Benchmark
Bicycle deal 'makes little sense' for Ionis, says Benchmark
07/13/21 William Blair
Bicycle collaboration a positive for Ionis, says William Blair
07/13/21 Piper Sandler
Bicycle Therapeutics price target raised to $46 from $39 at Piper Sandler
WAT Waters
$407.50 /

-2.335 (-0.57%)

SNY Sanofi
$48.22 /

+0.21 (+0.44%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

QGEN Qiagen
$53.51 /

+0.02 (+0.04%)

PFE Pfizer
$44.71 /

-0.06 (-0.13%)

PAHC Phibro Animal Health
$21.37 /

-0.03 (-0.14%)

IONS Ionis Pharmaceuticals
$36.23 /

-0.77 (-2.08%)

FOLD Amicus
$11.02 /

-0.13 (-1.17%)

EXEL Exelixis
$20.31 /

-0.18 (-0.88%)

BLUE Bluebird Bio
$17.50 /

-0.29 (-1.63%)

AZN AstraZeneca
$56.25 /

-0.21 (-0.37%)

ATR AptarGroup
$123.60 /

-1.1 (-0.88%)

ALNY Alnylam
$188.20 /

+0.595 (+0.32%)

ALLO Allogene Therapeutics
$24.58 /

-0.37 (-1.48%)

SNY Sanofi
$48.22 /

+0.21 (+0.44%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

PFE Pfizer
$44.71 /

-0.06 (-0.13%)

AZN AstraZeneca
$56.25 /

-0.21 (-0.37%)

SNY Sanofi
$48.22 /

+0.21 (+0.44%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

QGEN Qiagen
$53.51 /

+0.02 (+0.04%)

PFE Pfizer
$44.71 /

-0.06 (-0.13%)

IONS Ionis Pharmaceuticals
$36.23 /

-0.77 (-2.08%)

FOLD Amicus
$11.02 /

-0.13 (-1.17%)

FMS Fresenius Medical
$35.25 /

-0.42 (-1.18%)

EXEL Exelixis
$20.31 /

-0.18 (-0.88%)

BLUE Bluebird Bio
$17.50 /

-0.29 (-1.63%)

AZN AstraZeneca
$56.25 /

-0.21 (-0.37%)

ALNY Alnylam
$188.20 /

+0.595 (+0.32%)

ALLO Allogene Therapeutics
$24.58 /

-0.37 (-1.48%)

PFE Pfizer
$44.71 /

-0.06 (-0.13%)

IONS Ionis Pharmaceuticals
$36.23 /

-0.77 (-2.08%)

AZN AstraZeneca
$56.25 /

-0.21 (-0.37%)

Conference/Events
European Society for Medical Oncology to hold a virtual meeting » 10:09
09/16/21
09/16
10:09
09/16/21
10:09
ABBV

AbbVie

$107.05 /

-0.74 (-0.69%)

, AYLA

Ayala Pharmaceuticals

$14.30 /

+0.28 (+2.00%)

, DCPH

Deciphera

$30.40 /

-0.65 (-2.09%)

, GMAB

Genmab

$42.26 /

-0.57 (-1.33%)

, LPTX

Leap Therapeutics

$2.34 /

+0.39 (+20.00%)

, ORIC

Oric Pharmaceuticals

$25.02 /

+0.22 (+0.89%)

, SYNH

Syneos Health

$93.28 /

-0.43 (-0.46%)

, BGNE

BeiGene

$377.63 /

+3.31 (+0.88%)

, BMY

Bristol-Myers

$61.18 /

-0.82 (-1.32%)

, BYSI

BeyondSpring

$22.25 /

-0.73 (-3.18%)

, CALA

Calithera Biosciences

$2.06 /

-0.03 (-1.44%)

, GILD

Gilead

$71.34 /

-0.43 (-0.60%)

, GH

Guardant Health

$126.36 /

-0.65 (-0.51%)

, LLY

Eli Lilly

$231.73 /

-1.94 (-0.83%)

, IPSEY

Ipsen

$24.09 /

-0.115 (-0.48%)

, EXAS

Exact Sciences

$102.18 /

-2.46 (-2.35%)

, IDYA

Ideaya Biosciences

$25.87 /

-0.13 (-0.50%)

, GSK

GlaxoSmithKline

$38.92 /

-0.29 (-0.74%)

, RHHBY

Roche

$46.86 /

+0.11 (+0.24%)

, REGN

Regeneron

$647.54 /

-3.06 (-0.47%)

, PFE

Pfizer

$44.70 /

-0.07 (-0.16%)

, TAK

Takeda Pharmaceutical

$17.14 /

+0.14 (+0.82%)

, TMO

Thermo Fisher

$558.70 /

-4.135 (-0.73%)

, TCRR

TCR2 Therapeutics

$16.17 /

-0.05 (-0.31%)

, VERU

Veru

$8.70 /

-0.1 (-1.14%)

, VBLT

VBL Therapeutics

$2.30 /

+0.005 (+0.22%)

, VTRS

Viatris

$13.78 /

+0.05 (+0.36%)

, NVS

Novartis

$84.33 /

-0.735 (-0.86%)

ESMO 2021 Virtual…

ESMO 2021 Virtual Congress will be held on September 16-21. Webcast Link

ShowHide Related Items >><<
VTRS Viatris
$13.78 /

+0.05 (+0.36%)

VERU Veru
$8.70 /

-0.1 (-1.14%)

VBLT VBL Therapeutics
$2.30 /

+0.005 (+0.22%)

TMO Thermo Fisher
$558.70 /

-4.135 (-0.73%)

TCRR TCR2 Therapeutics
$16.17 /

-0.05 (-0.31%)

TAK Takeda Pharmaceutical
$17.14 /

+0.14 (+0.82%)

SYNH Syneos Health
$93.28 /

-0.43 (-0.46%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

REGN Regeneron
$647.54 /

-3.06 (-0.47%)

PFE Pfizer
$44.70 /

-0.07 (-0.16%)

ORIC Oric Pharmaceuticals
$25.02 /

+0.22 (+0.89%)

NVS Novartis
$84.33 /

-0.735 (-0.86%)

LPTX Leap Therapeutics
$2.34 /

+0.39 (+20.00%)

LLY Eli Lilly
$231.73 /

-1.94 (-0.83%)

IPSEY Ipsen
$24.09 /

-0.115 (-0.48%)

IDYA Ideaya Biosciences
$25.87 /

-0.13 (-0.50%)

GSK GlaxoSmithKline
$38.92 /

-0.29 (-0.74%)

GMAB Genmab
$42.26 /

-0.57 (-1.33%)

GILD Gilead
$71.34 /

-0.43 (-0.60%)

GH Guardant Health
$126.36 /

-0.65 (-0.51%)

EXAS Exact Sciences
$102.18 /

-2.46 (-2.35%)

DCPH Deciphera
$30.40 /

-0.65 (-2.09%)

CALA Calithera Biosciences
$2.06 /

-0.03 (-1.44%)

BYSI BeyondSpring
$22.25 /

-0.73 (-3.18%)

BMY Bristol-Myers
$61.18 /

-0.82 (-1.32%)

BGNE BeiGene
$377.63 /

+3.31 (+0.88%)

AYLA Ayala Pharmaceuticals
$14.30 /

+0.28 (+2.00%)

ABBV AbbVie
$107.05 /

-0.74 (-0.69%)

ABBV AbbVie
$107.05 /

-0.74 (-0.69%)

09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
09/08/21 JPMorgan
AbbVie offers 'best risk/reward story in the group,' says JPMorgan
09/07/21 Morgan Stanley
Morgan Stanley cuts Vertex Pharmaceuticals to Underweight amid AbbVie overhang
AYLA Ayala Pharmaceuticals
$14.30 /

+0.28 (+2.00%)

07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with Buy, $29 target at Ladenburg
07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with a Buy at Ladenburg
12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
DCPH Deciphera
$30.40 /

-0.65 (-2.09%)

08/04/21 H.C. Wainwright
Deciphera price target lowered to $70 from $75 at H.C. Wainwright
05/05/21 Barclays
Deciphera price target lowered to $65 from $70 at Barclays
05/05/21 H.C. Wainwright
Deciphera price target lowered to $75 from $80 at H.C. Wainwright
05/05/21 Piper Sandler
Deciphera price target lowered to $60 from $75 at Piper Sandler
GMAB Genmab
$42.26 /

-0.57 (-1.33%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
LPTX Leap Therapeutics
$2.34 /

+0.39 (+20.00%)

09/16/21 Piper Sandler
Leap data show 'very favorable early signal,' says Piper Sandler
09/13/21 Raymond James
Leap Therapeutics price target raised to $4 from $3 at Raymond James
09/13/21 Piper Sandler
Leap combo sees 'strong' early response rate, says Piper Sandler
06/03/21 Baird
Leap Therapeutics transferred with Outperform at Baird
ORIC Oric Pharmaceuticals
$25.02 /

+0.22 (+0.89%)

07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy after tumor data at Citi
07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
SYNH Syneos Health
$93.28 /

-0.43 (-0.46%)

08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
07/13/21 Barclays
Syneos Health price target raised to $102 from $90 at Barclays
06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
BGNE BeiGene
$377.63 /

+3.31 (+0.88%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
BMY Bristol-Myers
$61.18 /

-0.82 (-1.32%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
BYSI BeyondSpring
$22.25 /

-0.73 (-3.18%)

09/08/21 Baird
BeyondSpring initiated with an Outperform at Baird
08/04/21 Evercore ISI
BeyondSpring price target raised to $95 from $30 at Evercore ISI
08/04/21 William Blair
BeyondSpring may have new standard of care in lung cancer, says William Blair
08/04/21 H.C. Wainwright
Wainwright upgrades BeyondSpring with $100 target on lung cancer data
CALA Calithera Biosciences
$2.06 /

-0.03 (-1.44%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
GILD Gilead
$71.34 /

-0.43 (-0.60%)

07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
GH Guardant Health
$126.36 /

-0.65 (-0.51%)

08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
LLY Eli Lilly
$231.73 /

-1.94 (-0.83%)

09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
IPSEY Ipsen
$24.09 /

-0.115 (-0.48%)

08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
08/02/21 Societe Generale
Ipsen price target raised to EUR 101 from EUR 90 at Societe Generale
07/30/21 Credit Suisse
Ipsen price target raised to EUR 90 from EUR 75 at Credit Suisse
EXAS Exact Sciences
$102.18 /

-2.46 (-2.35%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/15/21 Canaccord
Exact Sciences progress in MRD space a positive, says Canaccord
09/01/21 Baird
UnitedHealth update to CRC screening coverage not a surprise, says Baird
IDYA Ideaya Biosciences
$25.87 /

-0.13 (-0.50%)

06/03/21 Baird
Ideaya Biosciences assumed with an Outperform at Baird
04/22/21 Roth Capital
Ideaya Biosciences price target raised to $38 from $31 at Roth Capital
04/19/21 H.C. Wainwright
Ideaya Biosciences price target raised to $35 from $29 at H.C. Wainwright
04/16/21 Roth Capital
Ideaya Biosciences price target raised to $31 from $23 at Roth Capital
GSK GlaxoSmithKline
$38.92 /

-0.29 (-0.74%)

08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
RHHBY Roche
$46.86 /

+0.11 (+0.24%)

09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
REGN Regeneron
$647.54 /

-3.06 (-0.47%)

09/15/21 Cantor Fitzgerald
Regeneron price target raised to $700 from $670 at Cantor Fitzgerald
09/15/21 H.C. Wainwright
Regeneron price target raised to $831 from $787 at H.C. Wainwright
09/15/21 Piper Sandler
Regeneron price target raised to $690 from $675 at Piper Sandler
09/09/21
Fly Intel: Top five analyst initiations
PFE Pfizer
$44.70 /

-0.07 (-0.16%)

09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/13/21 JPMorgan
Pfizer price target raised to $42 from $40 at JPMorgan
TAK Takeda Pharmaceutical
$17.14 /

+0.14 (+0.82%)

08/03/21 Piper Sandler
Arcturus strength attributable to large pharma's interest in mRNA, says Piper
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
TMO Thermo Fisher
$558.70 /

-4.135 (-0.73%)

08/04/21 Credit Suisse
Thermo Fisher assumed with an Outperform at Credit Suisse
08/04/21 Argus
Thermo Fisher price target raised to $600 from $530 at Argus
07/29/21 Cowen
Thermo Fisher price target raised to $560 from $525 at Cowen
07/29/21 BTIG
Thermo Fisher price target raised to $610 from $590 at BTIG
TCRR TCR2 Therapeutics
$16.17 /

-0.05 (-0.31%)

08/06/21 BMO Capital
TCR2 Therapeutics price target lowered to $44 from $53 at BMO Capital
06/24/21 Goldman Sachs
TCR2 Therapeutics initiated with a Buy at Goldman Sachs
06/11/21 BMO Capital
TCR2 Therapeutics coverage transferred at BMO Capital
05/14/21 Wedbush
TCR2 Therapeutics price target lowered to $45 from $57 at Wedbush
VERU Veru
$8.70 /

-0.1 (-1.14%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VBLT VBL Therapeutics
$2.30 /

+0.005 (+0.22%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
VTRS Viatris
$13.78 /

+0.05 (+0.36%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
NVS Novartis
$84.33 /

-0.735 (-0.86%)

09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
VTRS Viatris
$13.78 /

+0.05 (+0.36%)

VERU Veru
$8.70 /

-0.1 (-1.14%)

VBLT VBL Therapeutics
$2.30 /

+0.005 (+0.22%)

TMO Thermo Fisher
$558.70 /

-4.135 (-0.73%)

TCRR TCR2 Therapeutics
$16.17 /

-0.05 (-0.31%)

TAK Takeda Pharmaceutical
$17.14 /

+0.14 (+0.82%)

SYNH Syneos Health
$93.28 /

-0.43 (-0.46%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

REGN Regeneron
$647.54 /

-3.06 (-0.47%)

PFE Pfizer
$44.70 /

-0.07 (-0.16%)

ORIC Oric Pharmaceuticals
$25.02 /

+0.22 (+0.89%)

NVS Novartis
$84.33 /

-0.735 (-0.86%)

LPTX Leap Therapeutics
$2.34 /

+0.39 (+20.00%)

LLY Eli Lilly
$231.73 /

-1.94 (-0.83%)

IDYA Ideaya Biosciences
$25.87 /

-0.13 (-0.50%)

GSK GlaxoSmithKline
$38.92 /

-0.29 (-0.74%)

GILD Gilead
$71.34 /

-0.43 (-0.60%)

GH Guardant Health
$126.36 /

-0.65 (-0.51%)

EXAS Exact Sciences
$102.18 /

-2.46 (-2.35%)

DCPH Deciphera
$30.40 /

-0.65 (-2.09%)

CALA Calithera Biosciences
$2.06 /

-0.03 (-1.44%)

BYSI BeyondSpring
$22.25 /

-0.73 (-3.18%)

BMY Bristol-Myers
$61.18 /

-0.82 (-1.32%)

BGNE BeiGene
$377.63 /

+3.31 (+0.88%)

AYLA Ayala Pharmaceuticals
$14.30 /

+0.28 (+2.00%)

ABBV AbbVie
$107.05 /

-0.74 (-0.69%)

  • 08
    Jul
  • 03
    Jun
  • 04
    May
  • 09
    Apr
  • 01
    Mar
  • 18
    Feb
  • 20
    Jan
  • 02
    Dec
  • 02
    Dec
  • 19
    Nov
  • 13
    Nov
  • 07
    Oct
TMO Thermo Fisher
$558.70 /

-4.135 (-0.73%)

TAK Takeda Pharmaceutical
$17.14 /

+0.14 (+0.82%)

SYNH Syneos Health
$93.28 /

-0.43 (-0.46%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

REGN Regeneron
$647.54 /

-3.06 (-0.47%)

PFE Pfizer
$44.70 /

-0.07 (-0.16%)

NVS Novartis
$84.33 /

-0.735 (-0.86%)

LLY Eli Lilly
$231.73 /

-1.94 (-0.83%)

GSK GlaxoSmithKline
$38.92 /

-0.29 (-0.74%)

GILD Gilead
$71.34 /

-0.43 (-0.60%)

EXAS Exact Sciences
$102.18 /

-2.46 (-2.35%)

BMY Bristol-Myers
$61.18 /

-0.82 (-1.32%)

BGNE BeiGene
$377.63 /

+3.31 (+0.88%)

ABBV AbbVie
$107.05 /

-0.74 (-0.69%)

VERU Veru
$8.70 /

-0.1 (-1.14%)

TMO Thermo Fisher
$558.70 /

-4.135 (-0.73%)

TAK Takeda Pharmaceutical
$17.14 /

+0.14 (+0.82%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

REGN Regeneron
$647.54 /

-3.06 (-0.47%)

PFE Pfizer
$44.70 /

-0.07 (-0.16%)

ORIC Oric Pharmaceuticals
$25.02 /

+0.22 (+0.89%)

NVS Novartis
$84.33 /

-0.735 (-0.86%)

LPTX Leap Therapeutics
$2.34 /

+0.39 (+20.00%)

LLY Eli Lilly
$231.73 /

-1.94 (-0.83%)

IDYA Ideaya Biosciences
$25.87 /

-0.13 (-0.50%)

GSK GlaxoSmithKline
$38.92 /

-0.29 (-0.74%)

GMAB Genmab
$42.26 /

-0.57 (-1.33%)

GILD Gilead
$71.34 /

-0.43 (-0.60%)

GH Guardant Health
$126.36 /

-0.65 (-0.51%)

EXAS Exact Sciences
$102.18 /

-2.46 (-2.35%)

BYSI BeyondSpring
$22.25 /

-0.73 (-3.18%)

BMY Bristol-Myers
$61.18 /

-0.82 (-1.32%)

ABBV AbbVie
$107.05 /

-0.74 (-0.69%)

VTRS Viatris
$13.78 /

+0.05 (+0.36%)

VERU Veru
$8.70 /

-0.1 (-1.14%)

TAK Takeda Pharmaceutical
$17.14 /

+0.14 (+0.82%)

REGN Regeneron
$647.54 /

-3.06 (-0.47%)

PFE Pfizer
$44.70 /

-0.07 (-0.16%)

LLY Eli Lilly
$231.73 /

-1.94 (-0.83%)

GSK GlaxoSmithKline
$38.92 /

-0.29 (-0.74%)

GILD Gilead
$71.34 /

-0.43 (-0.60%)

BYSI BeyondSpring
$22.25 /

-0.73 (-3.18%)

BMY Bristol-Myers
$61.18 /

-0.82 (-1.32%)

ABBV AbbVie
$107.05 /

-0.74 (-0.69%)

Wednesday
Options
Cassava Sciences call volume above normal and directionally bullish » 10:05
09/15/21
09/15
10:05
09/15/21
10:05
SAVA

Cassava Sciences

$42.97 /

+1.15 (+2.75%)

Bullish option flow…

Bullish option flow detected in Cassava Sciences with 8,097 calls trading, 1.3x expected, and implied vol increasing almost 6 points to 161.05%. Sep-21 42 calls and Sep-21 45 calls are the most active options, with total volume in those strikes near 1,900 contracts. The Put/Call Ratio is 0.54. Earnings are expected on November 2nd.

ShowHide Related Items >><<
SAVA Cassava Sciences
$42.97 /

+1.15 (+2.75%)

SAVA Cassava Sciences
$42.97 /

+1.15 (+2.75%)

08/30/21 Cantor Fitzgerald
Cantor suspends rating on Cassava Sciences after allegations about simufilam
08/26/21 B. Riley
B. Riley says buy Cassava on 'numerous inconsistencies' in Citizen Petition
08/25/21 JonesTrading
Cassava addressed most key concerns in lawyer report, says JonesTrading
08/03/21 B. Riley
Cassava Sciences price target raised to $145 from $111 at B. Riley
SAVA Cassava Sciences
$42.97 /

+1.15 (+2.75%)

  • 13
    Nov
SAVA Cassava Sciences
$42.97 /

+1.15 (+2.75%)

SAVA Cassava Sciences
$42.97 /

+1.15 (+2.75%)

SAVA Cassava Sciences
$42.97 /

+1.15 (+2.75%)

Hot Stocks
Hookipa announces collaboration with Merck to evaluate HB-200 with KEYTRUDA » 07:04
09/15/21
09/15
07:04
09/15/21
07:04
HOOK

Hookipa Pharma

$6.21 /

-0.12 (-1.90%)

, MRK

Merck

$72.09 /

-0.43 (-0.59%)

HOOKIPA Pharma (HOOK), a…

HOOKIPA Pharma (HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced it has entered into a clinical collaboration and supply agreement with Merck (MRK) to evaluate the combination of HB-200, a novel arenaviral immunotherapeutic, and Merck USA's anti-PD-1 therapy, KEYTRUDA as first-line treatment for patients with advanced head and neck squamous cell carcinoma. "Our collaboration with Merck, Kenilworth, NJ., USA, a proven immuno-oncology leader, is an important step as we advance our HB-200 program for the treatment of Human Papillomavirus 16-positive cancers and seek to introduce a new class of immunotherapeutics," said Joern Aldag, CEO at HOOKIPA. "We have seen encouraging early responses in heavily pre-treated patients with the addition of KEYTRUDA in our ongoing HB-200 trial. We are excited to explore the potential benefit of HB-200 as a first-line treatment in combination with KEYTRUDA, a leading anti-PD-1 inhibitor globally, and the possibility of making a meaningful impact on patients' lives." The collaboration has been initiated based on data from the ongoing HB-200 Phase 1/2 clinical trial in advanced HPV16+ cancers. With a HB-200 program data read-out anticipated by Q4 2021, HOOKIPA anticipates initiating a Phase 2 trial with HB-200 in combination with KEYTRUDA in 2022. Additional Phase 2 expansion cohorts are also planned to start in Q1 2022.

ShowHide Related Items >><<
MRK Merck
$72.09 /

-0.43 (-0.59%)

HOOK Hookipa Pharma
$6.21 /

-0.12 (-1.90%)

HOOK Hookipa Pharma
$6.21 /

-0.12 (-1.90%)

04/08/21 Morgan Stanley
Hookipa Pharma initiated with an Overweight at Morgan Stanley
11/30/20 JMP Securities
Hookipa Pharma price target raised to $25 from $19 at JMP Securities
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Truist
Hookipa Pharma initiated with a Buy at Truist
MRK Merck
$72.09 /

-0.43 (-0.59%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley downgrades Merck to Equal Weight, awaits strategic action
09/07/21 Morgan Stanley
Merck downgraded to Equal Weight from Overweight at Morgan Stanley
MRK Merck
$72.09 /

-0.43 (-0.59%)

HOOK Hookipa Pharma
$6.21 /

-0.12 (-1.90%)

  • 09
    Dec
MRK Merck
$72.09 /

-0.43 (-0.59%)

MRK Merck
$72.09 /

-0.43 (-0.59%)

MRK Merck
$72.09 /

-0.43 (-0.59%)

Conference/Events
Morgan Stanley to hold a virtual conference » 04:55
09/15/21
09/15
04:55
09/15/21
04:55
ABC

AmerisourceBergen

$123.06 /

-0.61 (-0.49%)

, ACCD

Accolade

$46.70 /

-0.58 (-1.23%)

, AKBA

Akebia

$2.75 /

-0.165 (-5.66%)

, CMPS

Compass Pathways

$31.95 /

-1.1 (-3.33%)

, GH

Guardant Health

$127.03 /

+0.56 (+0.44%)

, KLDO

Kaleido Biosciences

$5.48 /

-0.045 (-0.81%)

, YMAB

Y-mAbs Therapeutics

$33.27 /

-0.05 (-0.15%)

, RYTM

Rhythm Pharmaceuticals

$12.30 /

-0.75 (-5.75%)

, OCDX

Ortho Clinical Diagnostics

$18.64 /

-0.08 (-0.43%)

, KDNY

Chinook Therapeutics

$12.78 /

-0.26 (-1.99%)

, IRTC

iRhythm

$61.34 /

-3.65 (-5.62%)

, NSTG

NanoString

$56.01 /

-0.16 (-0.28%)

, RMD

ResMed

$292.26 /

+3.15 (+1.09%)

, RDY

Dr. Reddy's

$66.87 /

-0.2 (-0.30%)

, HOLX

Hologic

$78.05 /

-0.49 (-0.62%)

, EXEL

Exelixis

$20.14 /

-0.11 (-0.54%)

, FHTX

Foghorn Therapeutics

$12.33 /

-0.67 (-5.15%)

, MAYNF

Mayne Pharma

/

+

, RCM

R1 RCM

$20.24 /

-0.17 (-0.83%)

, TIL

Instil Bio

$16.45 /

-1.28 (-7.22%)

, SNDX

Syndax

$19.00 /

+0.16 (+0.85%)

, SHCR

Sharecare

$8.02 /

-0.15 (-1.84%)

19th Annual Global…

19th Annual Global Healthcare Virtual Conference to be held on September 9-10 and will resume on September 13-15. Webcast Link

ShowHide Related Items >><<
YMAB Y-mAbs Therapeutics
$33.27 /

-0.05 (-0.15%)

TIL Instil Bio
$16.45 /

-1.28 (-7.22%)

SNDX Syndax
$19.00 /

+0.16 (+0.85%)

SHCR Sharecare
$8.02 /

-0.15 (-1.84%)

RYTM Rhythm Pharmaceuticals
$12.30 /

-0.75 (-5.75%)

RMD ResMed
$292.26 /

+3.15 (+1.09%)

RDY Dr. Reddy's
$66.87 /

-0.2 (-0.30%)

RCM R1 RCM
$20.24 /

-0.17 (-0.83%)

OCDX Ortho Clinical Diagnostics
$18.64 /

-0.08 (-0.43%)

NSTG NanoString
$56.01 /

-0.16 (-0.28%)

KLDO Kaleido Biosciences
$5.48 /

-0.045 (-0.81%)

KDNY Chinook Therapeutics
$12.78 /

-0.26 (-1.99%)

IRTC iRhythm
$61.34 /

-3.65 (-5.62%)

HOLX Hologic
$78.05 /

-0.49 (-0.62%)

GH Guardant Health
$127.03 /

+0.56 (+0.44%)

FHTX Foghorn Therapeutics
$12.33 /

-0.67 (-5.15%)

EXEL Exelixis
$20.14 /

-0.11 (-0.54%)

CMPS Compass Pathways
$31.95 /

-1.1 (-3.33%)

AKBA Akebia
$2.75 /

-0.165 (-5.66%)

ACCD Accolade
$46.70 /

-0.58 (-1.23%)

ABC AmerisourceBergen
$123.06 /

-0.61 (-0.49%)

ABC AmerisourceBergen
$123.06 /

-0.61 (-0.49%)

08/27/21 Baird
AmerisourceBergen a table pounding top pick, says Baird
08/05/21 Credit Suisse
AmerisourceBergen price target raised to $144 from $132 at Credit Suisse
08/05/21 Baird
AmerisourceBergen price target raised to $162 from $156 at Baird
07/20/21 Jefferies
Report of $21B opioid settlement positive for drug distributors, says Jefferies
ACCD Accolade
$46.70 /

-0.58 (-1.23%)

07/13/21 Baird
Accolade price target raised to $58 from $54 at Baird
07/09/21 Needham
Accolade price target raised to $68 from $59 at Needham
07/09/21 Stifel
Accolade price target raised to $64 from $54 at Stifel
07/09/21 Piper Sandler
Accolade has 'multiple beat-and-raise drivers,' says Piper Sandler
AKBA Akebia
$2.75 /

-0.165 (-5.66%)

07/15/21 Piper Sandler
Akebia approval path intact after FibroGen panel vote, says Piper Sandler
07/14/21 Morgan Stanley
FibroGen AdCom docs have likely read through for Akebia, says Morgan Stanley
06/01/21 H.C. Wainwright
Akebia NDA accepted with no FDA panel planned, says H.C. Wainwright
06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
CMPS Compass Pathways
$31.95 /

-1.1 (-3.33%)

07/13/21
Fly Intel: Top five analyst initiations
07/13/21 Citi
Compass Pathways initiated with a Buy at Citi
07/01/21 H.C. Wainwright
Compass Pathways price target raised to $100 from $65 at H.C. Wainwright
06/28/21
Fly Intel: Top five analyst initiations
GH Guardant Health
$127.03 /

+0.56 (+0.44%)

08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
KLDO Kaleido Biosciences
$5.48 /

-0.045 (-0.81%)

07/22/21 JMP Securities
Seres trial news 'disappointing,' but an isolated story, says JMP
07/09/21 Chardan
Kaleido Biosciences assumed with a Buy at Chardan
02/09/21 Piper Sandler
Kaleido Biosciences initiated with an Overweight at Piper Sandler
01/14/21 Chardan
Kaleido Biosciences price target raised to $17.50 from $10 at Chardan
YMAB Y-mAbs Therapeutics
$33.27 /

-0.05 (-0.15%)

06/28/21 H.C. Wainwright
Y-mAbs Therapeutics price target lowered to $68 from $70 at H.C. Wainwright
05/07/21 BofA
Y-mAbs Therapeutics upgraded to Buy from Neutral at BofA
04/23/21 Cowen
Y-mAbs Therapeutics transferred with Outperform at Cowen
04/21/21 Wedbush
Y-mAbs Therapeutics price target lowered to $52 from $67 at Wedbush
RYTM Rhythm Pharmaceuticals
$12.30 /

-0.75 (-5.75%)

09/14/21 Goldman Sachs
Rhythm Pharmaceuticals assumed with Neutral from Sell at Goldman Sachs
08/04/21
Fly Intel: Top five analyst downgrades
08/04/21 Ladenburg
Rhythm Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
08/04/21 BofA
Rhythm Pharmaceuticals downgraded to Underperform from Neutral at BofA
OCDX Ortho Clinical Diagnostics
$18.64 /

-0.08 (-0.43%)

08/05/21 Piper Sandler
Piper ups Ortho Clinical Diagnostics target to $29, says to buy on any weakness
08/05/21 JPMorgan
Ortho Clinical price target raised to $28 from $25 at JPMorgan
08/05/21 H.C. Wainwright
Ortho Clinical Diagnostics price target raised to $30 from $27 at H.C. Wainwright
08/04/21 Credit Suisse
Ortho Clinical Diagnostics assumed with an Outperform at Credit Suisse
KDNY Chinook Therapeutics
$12.78 /

-0.26 (-1.99%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 Wedbush
Wedbush bullish on Chinook Therapeutics, initiates with an Outperform
IRTC iRhythm
$61.34 /

-3.65 (-5.62%)

09/13/21 Baird
iRhythm's new COE has 'quality pedigree,' says Baird
09/13/21 Piper Sandler
DexCom COO departure won't affect momentum, says Piper Sandler
08/26/21 Canaccord
iRhythm price target raised to $236 from $210 at Canaccord
08/06/21 Citi
iRhythm price target lowered to $55 from $74 at Citi
NSTG NanoString
$56.01 /

-0.16 (-0.28%)

03/02/21 JPMorgan
NanoString price target raised to $80 from $75 at JPMorgan
03/02/21 Baird
NanoString price target raised to $78 from $70 at Baird
01/11/21 Baird
NanoString price target raised to $70 from $60 at Baird
01/06/21 Cowen
NanoString upgraded to Outperform with $75 target at Cowen
RMD ResMed
$292.26 /

+3.15 (+1.09%)

08/09/21 CLSA
ResMed upgraded to Underperform from Sell at CLSA
08/08/21 Macquarie
ResMed downgraded to Neutral from Outperform at Macquarie
08/02/21 CLSA
ResMed downgraded to Sell from Outperform at CLSA
08/02/21 Needham
ResMed downgraded to Hold at Needham on valuation
RDY Dr. Reddy's
$66.87 /

-0.2 (-0.30%)

07/27/21 Credit Suisse
Dr. Reddy's downgraded to Neutral at Credit Suisse after Q1 report
07/27/21 Credit Suisse
Dr. Reddy's downgraded to Neutral from Outperform at Credit Suisse
02/03/21 Investec
Dr. Reddy's upgraded to Buy from Hold at Investec
02/02/21 Barclays
Dr. Reddy's upgraded to Overweight from Equal Weight at Barclays
HOLX Hologic
$78.05 /

-0.49 (-0.62%)

07/06/21 Evercore ISI
Evercore ISI upgrades Hologic to Outperform on visibility in base business
07/06/21 Evercore ISI
Hologic upgraded to Outperform from In Line at Evercore ISI
06/11/21 Citi
Hologic 15% selloff brings 'strong entry point,' says Citi
04/29/21 Citi
Hologic price target lowered to $80 from $90 at Citi
EXEL Exelixis
$20.14 /

-0.11 (-0.54%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
FHTX Foghorn Therapeutics
$12.33 /

-0.67 (-5.15%)

11/17/20 Morgan Stanley
Foghorn Therapeutics initiated with an Overweight at Morgan Stanley
11/17/20 Wedbush
Wedbush bullish on Foghorn Therapeutics, initiates with an Outperform
11/17/20 Wedbush
Foghorn Therapeutics initiated with an Outperform at Wedbush
11/17/20 Cowen
Foghorn Therapeutics initiated with an Outperform at Cowen
MAYNF Mayne Pharma
/

+

08/30/21 Citi
Mayne Pharma upgraded to Buy from Neutral at Citi
RCM R1 RCM
$20.24 /

-0.17 (-0.83%)

07/22/21
Fly Intel: Top five analyst initiations
07/22/21 BofA
BofA starts R1 RCM at Buy, sees 32% upside potential
07/22/21 BofA
R1 RCM initiated with a Buy at BofA
06/02/21 Baird
R1 RCM initiated with an Outperform at Baird
TIL Instil Bio
$16.45 /

-1.28 (-7.22%)

08/13/21 Baird
Baird sees likely success for Instil Bio lead candidate, starts at Outperform
08/12/21 Baird
Instil Bio initiated with an Outperform at Baird
06/29/21 Chardan
Iovance data show activity but 'not a home run,' says Chardan
05/19/21 Chardan
Iovance Biotherapeutics price target lowered to $51 from $54 at Chardan
SNDX Syndax
$19.00 /

+0.16 (+0.85%)

06/03/21 Baird
Syndax transferred with Outperform at Baird
05/25/21 Citi
Syndax initiated with a Buy at Citi
04/21/21 Baird
Syndax price target lowered to $30 from $39 at Baird
02/24/21 Piper Sandler
Kura Oncology price target lowered to $30 from $34 at Piper Sandler
SHCR Sharecare
$8.02 /

-0.15 (-1.84%)

09/13/21 BTIG
Sharecare recent selloff creates buying opportunity, says BTIG
08/11/21 BTIG
Sharecare's Q2 results 'excellent,' 'impressive' level of visibility, says BTIG
08/04/21 Canaccord
Sharecare initiated with a Buy at Canaccord
07/28/21 BTIG
Sharecare initiated with a Buy at BTIG
YMAB Y-mAbs Therapeutics
$33.27 /

-0.05 (-0.15%)

TIL Instil Bio
$16.45 /

-1.28 (-7.22%)

SNDX Syndax
$19.00 /

+0.16 (+0.85%)

SHCR Sharecare
$8.02 /

-0.15 (-1.84%)

RYTM Rhythm Pharmaceuticals
$12.30 /

-0.75 (-5.75%)

RMD ResMed
$292.26 /

+3.15 (+1.09%)

RCM R1 RCM
$20.24 /

-0.17 (-0.83%)

OCDX Ortho Clinical Diagnostics
$18.64 /

-0.08 (-0.43%)

NSTG NanoString
$56.01 /

-0.16 (-0.28%)

KLDO Kaleido Biosciences
$5.48 /

-0.045 (-0.81%)

KDNY Chinook Therapeutics
$12.78 /

-0.26 (-1.99%)

IRTC iRhythm
$61.34 /

-3.65 (-5.62%)

HOLX Hologic
$78.05 /

-0.49 (-0.62%)

GH Guardant Health
$127.03 /

+0.56 (+0.44%)

EXEL Exelixis
$20.14 /

-0.11 (-0.54%)

CMPS Compass Pathways
$31.95 /

-1.1 (-3.33%)

AKBA Akebia
$2.75 /

-0.165 (-5.66%)

ACCD Accolade
$46.70 /

-0.58 (-1.23%)

ABC AmerisourceBergen
$123.06 /

-0.61 (-0.49%)

  • 10
    Sep
  • 10
    Jun
  • 27
    May
  • 30
    Apr
  • 19
    Mar
  • 18
    Feb
  • 04
    Feb
  • 05
    Feb
  • 28
    Jan
  • 09
    Dec
  • 22
    Oct
  • 23
    Oct
  • 07
    Oct
  • 08
    Oct
  • 18
    Sep
RDY Dr. Reddy's
$66.87 /

-0.2 (-0.30%)

IRTC iRhythm
$61.34 /

-3.65 (-5.62%)

CMPS Compass Pathways
$31.95 /

-1.1 (-3.33%)

ABC AmerisourceBergen
$123.06 /

-0.61 (-0.49%)

TIL Instil Bio
$16.45 /

-1.28 (-7.22%)

SNDX Syndax
$19.00 /

+0.16 (+0.85%)

RYTM Rhythm Pharmaceuticals
$12.30 /

-0.75 (-5.75%)

RMD ResMed
$292.26 /

+3.15 (+1.09%)

RCM R1 RCM
$20.24 /

-0.17 (-0.83%)

OCDX Ortho Clinical Diagnostics
$18.64 /

-0.08 (-0.43%)

KDNY Chinook Therapeutics
$12.78 /

-0.26 (-1.99%)

IRTC iRhythm
$61.34 /

-3.65 (-5.62%)

HOLX Hologic
$78.05 /

-0.49 (-0.62%)

GH Guardant Health
$127.03 /

+0.56 (+0.44%)

EXEL Exelixis
$20.14 /

-0.11 (-0.54%)

CMPS Compass Pathways
$31.95 /

-1.1 (-3.33%)

AKBA Akebia
$2.75 /

-0.165 (-5.66%)

ACCD Accolade
$46.70 /

-0.58 (-1.23%)

ABC AmerisourceBergen
$123.06 /

-0.61 (-0.49%)

SHCR Sharecare
$8.02 /

-0.15 (-1.84%)

RMD ResMed
$292.26 /

+3.15 (+1.09%)

HOLX Hologic
$78.05 /

-0.49 (-0.62%)

FHTX Foghorn Therapeutics
$12.33 /

-0.67 (-5.15%)

ACCD Accolade
$46.70 /

-0.58 (-1.23%)

ABC AmerisourceBergen
$123.06 /

-0.61 (-0.49%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.